Zoledronic acid injection (Reclast, Novartis) has been approved as the first therapy to prevent postmenopausal osteoporosis for two years with a single dose.
In a study involving more than 500 postmenopausal women with osteopenia, a single infusion significantly increased bone mineral density at two years compared with placebo.
Reclast is already approved as a once-yearly infusion to treat postmenopausal osteoporosis, increase bone mass in men with osteoporosis, and treat and prevent osteoporosis caused by glucocorticoids. Reclast is also approved for men and women with Paget’s disease of bone.
Patients should not take Reclast if they are also taking Zometa, which contains the same active ingredient. Reclast can be given in a physician’s office or at an infusion center.
Source: Novartis, June 1, 2009